Ziv-aflibercept
Zaltrap · VEGF trap
Hypertension and proteinuria like bevacizumab.
Cyramza · Ramu
Anti-VEGFR2 antibody · approved 2014 · 11 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
A VEGFR2-blocking antibody that strips the glomerular endothelium of VEGF, driving hypertension and proteinuria.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Hypertension and proteinuria are common class effects; nephrotic syndrome is a less frequent but reported event, sometimes after only 1-2 doses and typically accompanied by hypertension.Source: Muro et al., J Gastroenterol Hepatol 2016 (RAINBOW East Asian subgroup, all-grade hypertension 22%); Fujii et al., Medicine (Baltimore) 2019
Within the first one to two cycles (weeks).
Distilled from: “Within the first one to two cycles (weeks).”
Proteinuria and hypertension generally improve after dose interruption or withdrawal; a renal-limited thrombotic microangiopathy, when it occurs, warrants permanent discontinuation rather than resolving on rechallenge.PMID 31277139 (opens PubMed in a new tab)
Distilled from the agent's cited literature — educational, not a substitute for the primary sources.
Recovery across agentsThis agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
All-grade hypertension ~20.0% (high-grade ~8.6%) in meta-analysis of 11 studies, n=3,851; RR 2.77 vs control
Not the same figure as §01's 22%. §01 is any-grade hypertension in the East Asian patients of one gastric-cancer trial (with paclitaxel); this row pools 11 studies across cancers.
Proteinuria significantly increased vs control (all-grade RR 3.31, high-grade RR 5.28); grade >=3 proteinuria ~0.6% non-East-Asian and higher (~3.9%) in East Asian patients PMID 26302785 (opens PubMed in a new tab)
Renal-limited thrombotic microangiopathy with podocytopathy / nephrotic syndrome reported only at the case level PMID 39289295 (opens PubMed in a new tab)
Tap a signature to trace where it strikes the nephron.
Representative incidence
Hypertension strikes: Glomerulus, Vasculature / Endothelium.
Hypertension
Raised blood pressure — archetypally on-target loss of endothelial nitric oxide from VEGF-pathway blockade, studied as a pharmacodynamic marker of drug exposure. Other agents raise it too: vascular effects of BCR-ABL, BTK and RET inhibitors and of copanlisib; abiraterone's mineralocorticoid excess; androgen suppression or blockade.
Fully human IgG1 monoclonal antibody that binds the extracellular domain of VEGF receptor 2 (VEGFR2/KDR), blocking ligand binding by VEGF-A, VEGF-C and VEGF-D and inhibiting receptor activation, downstream signaling and tumor angiogenesis. Used in gastric/GEJ, colorectal, hepatocellular and non-small-cell lung cancers.
Class-level context for the major non-renal toxicities of the Anti-VEGFR2 antibody class.
Vascular
Hypertension, VTE/ATE, bleeding, aneurysm
Cardiac
Cardiomyopathy, QT, ischemia, myocarditis
Gastrointestinal
Diarrhea, colitis, mucositis, perforation
Dermatologic
Rash, HFS, SJS/TEN, vitiligo
7 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.
Kidney rows of the label's dosage tables
From the CYRAMZA label (Jun 2026) · DailyMed
The rows that name proteinuria, nephrotic syndrome, creatinine, creatinine clearance, renal or nephritis together with a withhold, reduce, resume or discontinue instruction, reproduced cell for cell. A merged cell is written out on each row it covers. The tables' footnotes are not reproduced, and they can hold the conditions for resuming: read the full table on DailyMed. Educational only, not medical advice.
| Adverse Reaction | Severitya | Dosage Modification |
|---|---|---|
| Proteinuria [see Warnings and Precautions (5.9)] | First occurrence of increased urine protein levels greater than or equal to 2 g per 24 hours | Withhold CYRAMZA until urine protein level is less than 2 g per 24 hours Resume CYRAMZA at a reduced dose: Reduce 8 mg/kg dose to 6 mg/kg Reduce 10 mg/kg dose to 8 mg/kg |
| Proteinuria [see Warnings and Precautions (5.9)] | Reoccurrence of urine protein level greater than 2 g per 24 hours following initial dose reduction | Withhold CYRAMZA until urine protein level is less than 2 g per 24 hours Resume CYRAMZA at a reduced dose: Reduce 6 mg/kg dose to 5 mg/kg Reduce 8 mg/kg dose to 6 mg/kg |
| Proteinuria [see Warnings and Precautions (5.9)] | Urine protein level greater than 3 g per 24 hours or in the setting of nephrotic syndrome | Permanently discontinue CYRAMZA |
Everything below is FAERS — adverse events someone chose to report, about 6,320 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Reported with a death outcome
1,693 of 6,320 reports
Reported with hospitalization
2,396 of 6,320 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial · 166 of the 6,320 reports predate 2015 and are not drawn.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Ramucirumab sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Zaltrap · VEGF trap
Hypertension and proteinuria like bevacizumab.
Avastin · Anti-VEGF antibody
Proteinuria, hypertension, glomerular TMA.
VEGFR TKI
Hypertension as an on-target marker; proteinuria.
Votrient · VEGFR TKI
VEGFR-TKI; hypertension, proteinuria, TMA.
Inlyta · VEGFR TKI
Potent VEGFR-TKI; hypertension and proteinuria dominate.
Ofev · VEGFR/FGFR/PDGFR TKI
Proteinuria and rare TMA.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.
The leading contributors to Ramucirumab’s clinical kidney literature on PubMed, ranked by a blend of publication volume and citation impact — filtered toward clinical work via the PubMed Humans heading and clinical publication types (trials, cohorts, case reports, guidelines, reviews). Names link to that author’s work on Ramucirumab; the PMIDs beside each name are up to three of their most recent papers on it, not the full count.
Ranked by a 50/50 blend of publication volume and a position-weighted, capped Relative Citation Ratio (NIH iCite) on this agent’s renal literature; the citation count shown is the raw total, not the ranking score — counted over the 68 clinical records among all 83 PubMed matches, so counts are within-sample — bibliometric context, not an endorsement or a measure of clinical authority.